Drug Profile

XY03 EA

Alternative Names: XY03-EA

Latest Information Update: 07 Jan 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Shijiazhuang Yiling Pharmaceutical
Class Benzofurans; Butyric acids; Esters; Ketones; Neuroprotectants; Small molecules; Vascular disorder therapies
Mechanism of Action Autophagy inhibitors; Oxygen radical scavengers

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase II/III Ischaemic stroke

Most Recent Events

15 Dec 2024 Phase-II/III clinical trials in Ischaemic stroke in China (PO) (NCT06755944)
25 Aug 2022 Shijiazhuang Yiling Pharmaceutical plans a phase II trial for Ischaemic stroke in October 2022 (PO) (NCT05515393)
25 Aug 2022 Phase-I clinical trials in Ischaemic stroke in China (PO) prior to August 2022 (Shijiazhuang Yiling Pharmaceutical pipeline, August 2022)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com